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Complement protein C1q is the first recognition subcomponent of the complement 
classical pathway that plays a vital role in the clearance of immune complexes, 
pathogens, and apoptotic cells. C1q also has a homeostatic role involving immune 
and non-immune cells; these functions not necessarily involve complement activation. 
Recently, C1q has been shown to be expressed locally in the microenvironment 
of a range of human malignant tumors, where it can promote cancer cell adhesion, 
migration, and proliferation, without involving complement activation. C1q has been 
shown to be present in the ascitic fluid formed during ovarian cancers. In this study, 
we have examined the effects of human C1q and its globular domain on an ovarian 
cancer cell line, SKOV3. We show that C1q and the recombinant globular head modules 
induce apoptosis in SKOV3 cells in a time-dependent manner. C1q expression was 
not detectable in the SKOV3 cells. Exogenous treatment with C1q and globular head 
modules at the concentration of 10 µg/ml induced apoptosis in approximately 55% cells, 
as revealed by immunofluorescence microscopy and FACS. The qPCR and caspase 
analysis suggested that C1q and globular head modules activated tumor necrosis factor 
(TNF)-α and upregulated Fas. The genes of mammalian target of rapamycin (mTOR), 
RICTOR, and RAPTOR survival pathways, which are often overexpressed in majority 
of the cancers, were significantly downregulated within few hours of the treatment of 
SKOV3 cells with C1q and globular head modules. In conclusion, C1q, via its globular 
domain, induced apoptosis in an ovarian cancer cell line SKOV3 via TNF-α induced 
apoptosis pathway involving upregulation of Bax and Fas. This study highlights a 
potentially protective role of C1q in certain cancers.
Keywords: complement, c1q, ovarian cancer, apoptosis, TnF, mTOr
inTrODUcTiOn
C1q is the first subcomponent of the C1 complex that recognizes the IgG- or IgM-containing 
immune complexes and initiates the complement classical pathway. It can bind to various self- and 
non-self ligands and bring about a range of homeostatic functions including clearance of pathogens 
and apoptotic cells (1). Human C1q molecule is composed of 18 polypeptide chains (6A, 6B, and 6C). 
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Each C1q chain has a short N-terminal region, a triple-helical 
collagen region, and a C-terminal globular (gC1q) domain (1, 2). 
Recently, a wide range of immunomodulatory functions of C1q 
have become evident that are independent of its involvement in 
the complement activation (3, 4); these include modulation of 
dendritic cell functions (5), cancer progression (6), and neuronal 
synapse pruning (7).
Ovarian cancer is the sixth most frequently diagnosed cancer 
among women worldwide and has the highest mortality rate 
than any other female reproductive system-associated cancer. 
Approximately 70% of the ovarian cancers are diagnosed at an 
advanced stage III or IV, with nearly 85% expected mortality 
(8). The intraperitoneally ascitic fluid (AF) formed during ovar-
ian cancer has been shown to have high levels of complement 
components such as C3a and soluble C5b–9, which form the 
membrane attack complex, suggesting potential for the activation 
of complement in vivo. However, complement activation appears 
to be dampened due to the expression of membrane regulators 
such as CD46, CD55, and CD59 on the ovarian cancer cells, ren-
dering complement system as an inefficient immune surveillance 
mechanism. The malignant ovarian tumor cells isolated from AF 
have been shown to have C1q and C2 deposited on the surface, 
which were rendered susceptible to complement-mediated kill-
ing by AF in the presence of anti-CD59-neutralizing antibody 
(9). In a recent study, the presence of C1q has been shown in 
the stroma and vascular endothelium of a number of human 
malignant tumors, including lung adenocarcinoma, melanoma, 
colon adenocarcinoma, breast adenocarcinoma, and pancreatic 
carcinoma (6). This has raised a tumor growth-fostering role for 
locally synthesized C1q via promotion of adhesion, migration, 
and proliferation.
The importance of complement in cancer immunotherapy 
has acquired great interest recently. A broad array of cell surface 
tumor-associated antigens that are overexpressed, mutated, or 
partially expressed, as compared to normal tissues, have offered 
various antibody targets in different cancers (10). A number of 
these anti-cancer antibodies work via receptor or checkpoint 
blockade or as an agonist, apoptosis induction, immune-medi-
ated cytotoxicity either via complement or antibody, and T cell 
function regulation. In addition, therapeutic antibodies targeting 
growth factors and their receptors such as epidermal growth fac-
tor receptor, insulin-like growth factor 1 receptor, tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand receptors, and 
receptor activator nuclear factor-κB ligand (RANKL) have also 
been exploited for cancer treatment (11).
In this study, we sought to investigate the complement-
independent effects of exogenous C1q and recombinant forms 
of globular head modules on an ovarian cancer cell line, SKOV3.
MaTerials anD MeThODs
cell culture and Treatments
A human ovarian clear cell adenocarcinoma cell line, SKOV3 
(ATCC, Rockville, MD, USA) was used as an in vitro model for 
epithelial ovarian cancer. Cells were cultured in DMEM-F12 
media containing 10% v/v fetal calf serum, 2mM l-glutamine, 
and penicillin (100  U/ml)/streptomycin (100  µg/ml) (Thermo 
Fisher). Cells were grown at 37°C under 5% v/v CO2 until 80–90% 
confluency was reached.
Purification of human c1q
Human C1q was purified as published earlier (12). Briefly, freshly 
thawed human plasma was made 5  mM EDTA, centrifuged at 
5,000 × g for 10 min, and any aggregated lipids were removed 
using Whatmann filter paper (GE Healthcare, UK). The plasma 
was then incubated with non-immune IgG-Sepharose (GE 
Healthcare, UK) for 2 h at room temperature. C1q bound IgG-
Sepharose was washed extensively with 10 mM HEPES, 140 mM 
NaCl, 0.5 mM EDTA, and pH 7.0 before eluting C1q with CAPS 
(N-cyclohexyl-3-aminopropanesulfonic acid) buffer (100  mM 
CAPS, 1 M NaCl, 0.5 mM EDTA, pH 11). The eluted C1q frac-
tions were then passed through a HiTrap Protein G column 
(GE Healthcare, UK) to remove IgG contaminants, followed by 
dialysis against 0.1 M HEPES buffer, pH 7.5.
recombinant expression and 
Purification of gha, ghB, and ghc 
Modules of human c1q
The recombinant forms of the globular head regions of human 
C1q A (ghA), B (ghB), and C (ghC) chains were expressed 
as fusions to Escherichia coli maltose-binding protein (MBP) 
and purified, as reported previously (13). Expression constructs 
pKBM-A, pKBM-B, and pKBM-C were transformed into E. coli 
BL21 (Invitrogen) cells in the presence of ampicillin (100 µg/ml). 
The primary bacterial culture was grown overnight by inoculat-
ing a single colony in 25 ml of Luria-Bertani medium contain-
ing ampicillin. The bacterial culture was then grown in a 1  L 
batch until OD600 0.6 and then induced with 0.4 mM isopropyl 
β-d-thiogalactoside (IPTG) (Sigma-Aldrich, UK) for 3  h at 
37°C on a shaker and centrifuged (5,000  ×  g, 4°C, 15  min). 
Subsequently, the cell pellet for each fusion protein was lysed 
in 50 ml lysis buffer (20  mM Tris–HCl, pH 8.0, 0.5  M NaCl, 
0.2% v/v Tween 20, 1  mM EGTA pH 7.5, 1  mM EDTA pH 
7.5, and 5% v/v glycerol) containing lysozyme (100  µg/ml, 
Sigma-Aldrich, UK) and 0.1 mM phenylmethylsulfonyl fluoride 
(PMSF; Sigma-Aldrich, UK) at 4°C for 30 min. The resultant cell 
suspension was sonicated at 60 Hz for 30 s with an interval of 
2 min each (12 cycles) and centrifuged (16,000 × g for 30 min). 
The supernatant was diluted 5-fold with buffer I (20 mM Tris–
HCl, pH 8.0, 100 mM NaCl, 0.2% v/v Tween 20, 1 mM EDTA 
pH  7.5, and 5% v/v glycerol) and passed through an amylose 
resin column (50  ml; New England Biolabs). The column was 
then washed extensively with buffer I (150  ml), followed by 
buffer II (250  ml of buffer I without Tween 20) before eluting 
1 ml fractions of fusion proteins with 100 ml buffer II containing 
10  mM maltose. The peak fractions were then passed through 
Pierce™ High Capacity Endotoxin Removal Resin (Qiagen) 
to remove lipopolysaccharide. Endotoxin levels in the purified 
protein samples were analyzed using the QCL-1000 Limulus 
amebocyte lysate system (Lonza). The assay was linear over a 
range of 0.1–1.0 EU/ml (10 EU =  1 ng of endotoxin), and the 
amount of endotoxin levels was <4  pg/μg of the recombinant 
proteins.
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Fluorescence Microscopy
SKOV3 cells (0.5 × 105) were grown on coverslips and incubated 
with human C1q, ghA, ghB, or ghC (10 µg/ml) in a serum-free 
DMEM-F12 medium for 1 h for analyzing cell binding, 24 h for 
apoptosis induction, and 15 h for mammalian target of rapamycin 
(mTOR) activation analysis. For binding analysis, the coverslips 
were washed three times with PBS and then incubated with rabbit 
anti-human C1q polyclonal antibody (MRC Immunochemistry 
Unit, Oxford, 1:200) for C1q and rabbit anti-MBP polyclonal 
antibody (Thermo Fisher) for MBP fusions of the globular head 
modules. Coverslips were washed three times with PBS, and 
then incubated with Alexa Fluor® 488 (1:500, Thermo Fisher) 
and Hoechst (1:10,000, Thermo Fisher) for immunofluorescence 
analysis. Apoptosis was analyzed via immunofluorescence using 
a FITC-Annexin V apoptosis detection kit with propidium 
iodide (PI) (Biolegend). After 24 h incubation with proteins, the 
coverslips were then incubated with Annexin V-binding buffer 
containing FITC Annexin V (1:200) and PI (1:200) for 15 min 
and washed twice with PBS before mounting on the slides to 
visualize under a HF14 Leica DM4000 microscope. For mTOR 
analysis, following the 15-h incubation with proteins, the cov-
erslips were washed three times with PBS. The cells were fixed 
and permeabilized using ice-cold 100% methanol at −20°C for 
10  min, followed by 1  h incubation with rabbit anti-human 
mTOR (1:500, Sigma), and then 1 h incubation with Alexa Fluor® 
488 (rabbit anti-human 1:500, Thermo Fisher) and Hoechst 
(1:10,000, Thermo Fisher) for immunofluorescence analysis. In 
order to detect caspase 3 activation, the protein-treated SKOV3 
cells were fixed and permeabilized using ice-cold 100% methanol 
at −20°C for 10 min, followed by 1 h incubation with rabbit anti-
human cleaved caspase 3 (1:500, Cell Signaling), and then 1 h 
incubation with secondary antibody (anti-rabbit) probed with 
CY3 (1:500, Thermo Fisher) and Hoechst (1:10,000, Thermo 
Fisher) for immunofluorescence analysis.
Dye exclusion assay
SKOV3 cells (0.1 × 106) were grown in a 12-well plate and incu-
bated with C1q, ghA, ghB, ghC, or MBP (10 µg/ml) along with an 
untreated control in serum-free DMEM-F12 for 24 h. Cells were 
detached using 5 mM EDTA, pH 8.0 and centrifuged at 1,200 × g 
for 5 min. The cell pellet was re-suspended in 1 ml DMEM-F12, 
and 10  µl of cell suspension was stained with 10  µl of Trypan 
blue (60%; Sigma-Aldrich, UK) for cell counting using hemocy-
tometer. The viable cells, i.e., unstained cells, were counted in 5 
different optical fields with a threshold value of 200 cells per field.
MTT assay
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (Thermo Fisher) assay was performed by incubating 
SKOV3 cells (0.1 × 105) in a 96-well microtiter plate with C1q, 
ghA, ghB, ghC, or MBP (10 µg/ml each) and an untreated control 
in serum-free DMEM-F12 medium for 24 h, followed by incuba-
tion with 50 µg/µl MTT (5 mg/ml stock) per well for 4 h at 37°C. 
Majority of the media was removed leaving behind 25 µl per well, 
which was mixed thoroughly with 50  µl of dimethyl sulfoxide 
(DMSO) and incubated for another 10 min at 37°C. The absorb-
ance was read at 570 nm using a plate reader.
Flow cytometry
SKOV3 cells (0.1 × 107) were incubated with C1q, ghA, ghB, or 
ghC (10  µg/ml), along with an untreated control, in a six-well 
plate for 24 h, followed by cell detachment using 5 mM EDTA 
and centrifugation at 1,200  ×  g for 5  min. FITC Annexin V 
apoptosis detection kit with PI (Biolegend) was used, as per the 
manufacturer’s instructions. Compensation parameters were 
acquired using unstained, untreated FITC stained, and untreated 
PI stained SKOV3 cells. SKOV3 cells (0.1 × 104) were acquired for 
each experiment and compensated before plotting the acquired 
data. For protein-binding analysis, SKOV3 cells (0.5  ×  106) 
were incubated with C1q, ghA, ghB, and ghC (10  µg/ml) and 
BSA-treated cells as a negative control. Cells were incubated at 
4°C for 1 h, followed by 1 h incubation with rabbit anti-human 
C1q polyclonal antibody (1:200) for C1q and rabbit anti-MBP 
(Thermo Fisher, 1:200) for globular head modules treated cells 
as well as their respective BSA-treated controls. The cells were 
then incubated with Alexa Fluor® 488 (1:1,000, Thermo Fisher) 
for 1 h and cells were washed with PBS three times between each 
step. Compensation parameters were acquired using unstained, 
untreated Alexa Fluor® 488-stained SKOV3 cells. SKOV3 cells 
(0.1 × 104) were acquired using Novocyte Flow Cytometer for each 
experiment and compensated before plotting the acquired data.
Western Blot
SKOV3 cells (0.1 ×  107) were plated in a six-well plate (Nunc) 
and incubated with C1q, ghA, ghB, or ghC (10 µg/ml), along with 
an untreated control in serum-free DMEM-F12 medium for 12 
and 24 h. The cells were lysed within the wells using lysis buffer 
(50 mM Tris–HCL, pH 7.5, 10% v/v glycerol, and 150 mM NaCl) 
over ice for 10 min, before being gently transferred to a pre-cooled 
microcentrifuge tube, and centrifuged for 15 min at 13,000 × g at 
4°C. The cell lysate was mixed with the treatment buffer (50 mM 
Tris pH 6.8, 2% β-merceptoethanol, 2% SDS, 0.1% bromophenol 
blue, and 10% glycerol) in order to run on SDS-PAGE (12% w/v) 
for 90 min at 120 V. The SDS-PAGE separated proteins were then 
electrophoretically transferred onto a nitrocellulose membrane 
(Sigma) using transfer buffer (25 mM Tris, 190 mM glycine, and 
20% methanol, pH 8.3) for 2 h at 320 mA, followed by blocking 
with 5% w/v dried milk powder (Sigma) in 100-ml PBS at room 
temperature for 2  h on a rotatory shaker. The membrane was 
washed with PBST (PBS + 0.05% Tween 20) three times, 10 min 
each, and incubated with primary anti-human C1q (polyclonal 
antibody), anti-caspase 9, anti-caspase 3, or anti-cleaved caspase 
3 antibodies (1:1000 Cell Signaling Technology) at 4°C overnight. 
The membrane was washed with PBST (three times, 10 min each) 
before incubating with secondary anti-rabbit IgG HRP-conjugate 
(1:1,000; Promega) for 1 h at room temperature. The bands were 
visualized using enhanced chemiluminescence (Thermo Fisher) 
in the Biorad ChemiDoc MP imaging system, or using 3,3-diam-
inobenzidine (DAB) substrate kit (Thermo Fisher).
Quantitative rT-Pcr
SKOV3 cells (0.5 ×  106) were incubated with C1q, ghA, ghB, 
or ghC (10 µg/ml) for various time points, and the centrifuged 
cell pellets were stored at −80°C. GenElute Mammalian Total 
RNA Purification Kit (Sigma-Aldrich, UK) was used, as per 
TaBle 1 | Target genes and terminal primers used in the qPcr analysis.
Target gene Forward primer reverse primer
18S 5′-ATGGCCGTTCTTAGTTGGTG-3′ 5′-CGCTGAGCCAGTCAGTGTAG-3′
Bax 5′-TGCTTCAGGGTTTCATCCAGG-3′ 5′-GGAAAAAGACCTCTCGGGGG-3′
Fas 5′-ACACTCACCAGCAACACCAA-3′ 5′-TGCCACTGTTTCAGGATTTAA-3′
Mammalian target of rapamycin (mTOR) 5′-TGCCAACTATCTTCGGAACC-3′ 5′-GCTCGCTTCACCTCAAATTC-3′
RICTOR 5′-GGAAGCCTGTTGATGGTGAT-3′ 5′-GGCAGCCTGTTTTATGGTGT-3′
RAPTOR 5′-ACTGATGGAGTCCGAAATGC-3′ 5′-TCATCCGATCCTTCATCCTC-3′
Tumor necrosis factor (TNF)-α 5′-GTATCGCCAGGAATTGTTGC-3′ 5′-AGCCCATGTTGTAGCAAACC-3′
NF-κB 5′-TGAGGTACAGGCCCTCTGAT-3′ 5′-GTATTTCAACCACAGATGGCACT-3′
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the manufacturer’s instructions, to extract total RNA, followed 
by treatment with DNase I (Sigma-Aldrich, UK) to remove any 
DNA contaminants. The concentration and purity of total RNA 
were determined by measuring the absorbance at 260  nm and 
260:280  nm ratio, respectively, using NanoDrop 2000/2000c 
(Thermo Fisher Scientific). Total RNA (2 µg) was used to syn-
thesize cDNA using High Capacity RNA to cDNA Kit (Applied 
Biosystems).
Forward and reverse primer sequences (Table  1) were 
designed using the web-based Basic Local Alignment Search Tool 
and Primer-BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The 
qPCR reactions were performed to measure the mRNA expres-
sion level of various target genes. Each reaction was conducted in 
triplicates and consisted of 5 µl Power SYBR Green MasterMix 
(Applied Biosystems), 75 nM of forward and reverse primers, and 
500 ng cDNA, making up to a 10 µl final volume per well. Relative 
mRNA expression was determined by qPCR using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems). Samples were 
initially incubated at 50°C and 95°C for 2 and 10 min, respectively, 
followed by amplification of the template for 40 cycles (each cycle 
involved 15 s at 95°C and 1 min at 60°C). The gene expression 
was normalized using the expression of human 18S rRNA as an 
endogenous control. The cycle threshold (Ct) mean value for each 
target gene was used to calculate the relative expression using 
the relative quantification (RQ) value and formula: RQ = 2−ΔΔCt, 
which was compared with the relative expression of 18S.
statistical analysis
GraphPad Prism 6.0 was used to make graphs, and the statistical 
analysis was carried out using an unpaired one-way ANOVA 
test. Significant values were considered based on *p  <  0.05, 
*p  <  0.01, and ***p  <  0.001 between treated and untreated 
conditions. Error bars show the SD or SEM, as indicated in the 
figure legends.
resUlTs
human c1q and recombinant globular 
head Modules Bind sKOV3
The qualitative binding analysis of C1q and recombinant form of 
individual globular head (ghA, ghB, and ghC) modules (10 µg/ml) 
to SKOV3 cells using immunofluorescence microscopy revealed 
the membrane localization of these proteins following 1 h incu-
bation at 4°C (Figure  1A). The nucleus, stained with Hoechst, 
showed a blue fluorescence (Figure  1A, panel A). The bound 
proteins localized on the cell membrane via green fluorescence; 
all the four proteins showed similar binding pattern (Figure 1A, 
panels B and D). FACS analysis revealed similar binding pattern, 
consistent with the observations made under the immunofluo-
rescence microscopy. SKOV3 cells, treated with C1q and globular 
head modules, were over 90% positive in the FITC positive 
quadrant, as compared to the control protein, BSA (Figure 1B).
c1q and recombinant globular head 
Modules reduce cellular Viability via 
induction of apoptosis in sKOV3 cells
C1q and globular head modules (at 10 µg/ml concentration) were 
incubated with SKOV3 cells for 24 h. Trypan blue dye exclusion 
(Figure 2A) revealed a significant decrease in the cell viability fol-
lowing incubation with C1q (~50%), ghA (~50%), ghB (~40%), 
and ghC (~55%). MTT assay also confirmed the above mentioned 
observations (Figure 2B). Furthermore, the qualitative apoptosis 
analysis was performed using immunofluorescence microscopy. 
A significant proportion of SKOV3 cells, when treated with C1q 
proteins (10 µg/ml) for 24 h, stained positive for cell membrane 
integrity marker, Annexin V (conjugated to FITC), which binds 
to phosphatidylserine (PS) of the membrane of cells undergoing 
apoptosis (Figure  3, panel B). The nucleus was stained using 
Hoechst, which showed blue fluorescence (Figure 3, panel A). No 
FITC fluorescence was detected in the untreated cells, suggesting 
that the integrity of the cell membrane was intact, and hence, the 
cells were still viable (Figure 3).
FACS analysis revealed that the treatment of SKOV3 cells 
with C1q (10 µg/ml) for 24 h yielded approximately 58% (C1q, 
quadrant Q2-2; Figure 4) cells positive for both FITC (Annexin V 
marker) and PI (stains DNA) quadrant, significantly higher than 
1.42% untreated control cells (UT, quadrant Q2-2; Figure  4), 
which represented a cell population undergoing late apoptosis. 
In addition, 16% of cells stained positive for FITC only (C1q, 
quadrant Q2-4; Figure 4), which represented an early apoptotic 
cell population.
Similar trends were also observed when SKOV3 cells were 
treated with ghA, ghB, and ghC; approximately 50% (ghA and 
ghC) and 40% (ghB) of cells had undergone apoptosis after 
24 h treatment as seen in quadrant Q2-2 (ghA, ghB, and ghC in 
Figure 4). Approximately, 15–20% of early apoptotic cells stained 
positive for FITC alone (quadrant Q2-4; Figure  4) following 
treatment with each globular head module. In the untreated cells, 
approximately 90% of the cell population was both FITC and PI 
negative (UT, quadrant Q2-3; Figure 4). A shift in the florescence 
FigUre 1 | (a) Binding of human C1q and recombinant globular head modules, ghA, ghB, and ghC (10 µg/ml; 1 h incubation) to SKOV3 cells using 
immunofluorescence microscopy. Panel A shows the nucleus of the cells stained with Hoechst. Panel B shows the cells probed with anti-C1q (C1q) and anti-
maltose-binding protein (MBP) (globular heads) polyclonal antibodies, followed by anti-rabbit IgG labeled with FITC; the bound proteins are visible on the cell 
membrane (panels C and D). (B) Flow cytometric analysis to show binding of human C1q and ghA, ghB, and ghC (10 µg/ml) to SKOV3 cells after 1 h incubation. 
Panel a shows the number of cells probed with anti-C1q (C1q) and anti-MBP (globular heads) antibodies followed by anti-rabbit IgG labeled with FITC, as compared 
to the untreated cells. Panel b shows the shift in the fluorescent intensity from untreated to treated cells.
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FigUre 3 | analysis of apoptosis using immunofluorescence 
microscopy in sKOV3 cells treated with human c1q, gha, ghB, and 
ghc (10 µg/ml) and an untreated control after 24 h. Panel A shows the 
nucleus stained with Hoechst. Panel B shows the cell membrane integrity 
marker FITC Annexin V, which binds to PS of the cell membrane of cells 
undergoing apoptosis. No FITC was detected in the untreated SKOV3 cells.
FigUre 2 | sKOV3 cell viability assay via Trypan blue exclusion (a) 
and MTT (B) following treatment with human c1q, gha, ghB, ghc, and 
maltose-binding protein (MBP) (10 μg/ml)and untreated control for 
24 h (±seM, of three independent experiments). Cell numbers were 
reduced by approximately 50% in the treated as compared to untreated and 
MBP controls. Significance was established using the unpaired one-way 
ANOVA test (*p < 0.05, *p < 0.01, and ***p < 0.001) (n = 6).
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intensity in the treated SKOV3 cells, as compared to the untreated 
cells, further confirmed these observations (Figure 4).
c1q and individual globular head Modules 
Upregulate TnF-α Transcripts by sKOV3 
cells with concomitant Upregulation of 
nF-κB
The mRNA expression level of pro-inflammatory cytokine, 
TNF-α, was significantly upregulated at 12 h following C1q (log10 
1.2-fold) and globular head modules; ghA (log10 0.4-fold), ghB 
(log10 1-fold), and ghC (log10 0.7-fold) treatment in comparison 
to an untreated control, as determined by qPCR (Figure  5A). 
NF-κB was also significantly upregulated (log10 0.7-fold) at 12 h, 
as anticipated, consistent with TNF-α upregulation (Figure 5B). 
Both TNF-α (not shown) and NF-κB mRNA expressions were 
downregulated by 24 h (Figure 5C), which could be attributed 
to the late apoptosis stage. In addition, TNF-α transcriptional 
upregulation occurred at an earlier time point for ghA, i.e., at 6 h 
as compared to the other treated samples (data not shown). These 
results prompted us to further investigate the mRNA expression 
of pro-apoptotic makers of intrinsic (Bax) and extrinsic (Fas) 
apoptosis pathways.
c1q Upregulates expression of Pro-
apoptotic Bax and Fas in sKOV3 cells
C1q- and globular head module-mediated apoptosis was further 
investigated by analyzing the expression of pro-apoptotic genes, 
Bax and Fas, via qPCR. Fas was transcriptionally upregulated in 
the C1q (log10 0.4-fold) treated SKOV3 cells, most significantly 
at 12 and 24 h relative to the untreated control cells (Figure 6A). 
The globular head module-treated cells showed minimal mRNA 
expression levels at 12 h (data not shown) and significant upreg-
ulation of Fas at 24 h (log10 0.4-fold) (Figure 6B). Similar trend 
of minimal mRNA expression at 12 h (data not shown) and sig-
nificant upregulation at 24 h (Figure 6C) were observed for Bax 
mRNA expression in case of ghA, ghB, or ghC. The activation 
of apoptotic pathway causes the loss of cell membrane integrity, 
which was previously observed in the immunofluorescence 
FigUre 4 | The quantitative analysis of apoptosis using Facs. SKOV3 cells, treated with C1q and globular head modules for 24 h, yielded approximately 50% 
(C1q, ghA, ghB, and ghC quadrant Q2-2) cells positive for both FITC and PI, significantly higher than 1.42% untreated control cells (untreated, quadrant Q2-2). 
Approximately 20% cells stained positive for FITC only (C1q, ghA, ghB, and ghC quadrant Q2-4).
7
Kaur et al. C1q and Ovarian Cancer
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 599
microscopy at 24 h, consistent with the upregulation of mRNA 
expression of these genes. To further validate these results, the 
activation of Caspase 3 was investigated via western blot.
c1q and the globular head Modules 
activate caspase 3 in sKOV3 cells
Apoptotic markers, caspase 3 and cleaved caspase 3, were detected 
in the SKOV3 cells, treated with C1q and globular head modules, 
in comparison with the untreated cells. The cleaved caspase 3 was 
detected at 17 kDa after 24 h of C1q, ghA, and ghB treatment in 
the western blot (Figure 7B). A reduction in the abundance of the 
full length at 32 kDa was seen after 24 h in comparison to 12 h 
(Figure 7A) β-actin (45 kDa) was used as a loading control for 
12 h and 24 h (Figure 7C). In addition, the activation of caspase 
3 was also seen by immunofluorescence in parallel to apoptosis 
staining for Annexin V-FITC at 24 h following treatment with 
C1q or globular head modules. Activated caspase 3 was clearly 
visible in the cytoplasm probed with Cy3, suggesting that the 
SKOV3 cells were in the early stages of apoptosis as the membrane 
was stained positively for Annexin V-FITC, in comparison to the 
control where no staining was detected (Figure 7D). The cleaved 
caspase 3 in the ghC treatment sample could not be detected 
via western blot; however, activated caspase 3 was detected via 
immunofluorescence.
c1q, gha, ghB, and ghc Downregulate 
Prosurvival Factors such as ricTOr, 
mTOr, and raPTOr
In addition to the apoptosis markers, we also investigated the 
expression of mTOR signaling pathways since it is frequently 
detected in ovarian cancers (14). The mRNA expressions of 
mTOR, RICTOR, and RAPTOR (Figure 8A) were significantly 
downregulated (~log10 0.5-fold) at 6  h, thereby suggesting that 
the effects of C1q and globular head modules can compromise 
mTOR signaling within the first few hours of the treatment. 
Additionally, the presence of mTOR was detected abundantly in 
the cytoplasm (green) of the untreated cells, compared to SKOV3 
cells treated with C1q and globular heads at 15 h time point via 
immunofluorescence microscopy (Figure 8B).
DiscUssiOn
We report here, for the first time, that exogenous treatment with 
human C1q and recombinant globular head modules ghA, ghB, 
FigUre 6 | relative quantification comparisons of Fas (a) and Bax 
(B,c) mrna expression in sKOV3 cells treated with c1q, gha, ghB, 
and ghc (10 µg/ml). Fas expression was upregulated (~log10 0.5-fold) at 
12 h (C1q only) and 24 h (both for C1q and globular head modules). Bax 
expression was upregulated (~log10 0.5-fold) at 24 h. Significance was 
determined using the unpaired one-way ANOVA test (*p < 0.05, *p < 0.01, 
and ***p < 0.001) (n = 3).
FigUre 5 | relative quantification comparisons of TnF-α (a) and 
nF-κB (B,c) mrna expression in sKOV3 cells treated with c1q, gha, 
ghB, and ghc. The transcriptional expressions of both TNF-α and NF-κB 
were upregulated (log10 0.5- to 1-fold) after 12 h treatment and NF-κB at 24 h 
was downregulated. Significance was ascertained using the unpaired 
one-way ANOVA test (*p < 0.05, *p < 0.01, and ***p < 0.001) (n = 3).
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and ghC caused apoptosis in an ovarian cancer cell line, SKOV3. 
This was evident from a significant increase in the number of 
Annexin V-positive cells that were examined via immunofluores-
cence microscopy and FACS, presence of cleaved caspase 9 (data 
not shown) and 3 via western blot, and transcriptional upregula-
tion of pro-apoptotic markers, such as TNF-α, Bax, and Fas as 
illustrated in Figure 9. Based on these observations, it appears 
likely that C1q and individual globular head modules can induce 
apoptosis in SKOV3 cells via TNF-α-induced apoptosis pathway. 
However, other pathways could potentially be involved.
FigUre 7 | caspase activation in sKOV3 cells following treatment with c1q and globular head modules. (a) Western blot analysis of full-length/total 
caspase 3 at 32 kDa after 12 and 24 h of the treatment with C1q, ghA, ghB, ghC, and untreated. (B) The cleaved caspase 3 was observed at 17 kDa after 24 h of 
treatment with C1q, ghA, ghB, ghC, and untreated (c) Western blot analysis for β-actin as a loading control for 12 h and 24 h at 45 kDa. (D) The activation of 
caspase 3 was also shown by immunofluorescence microscopy at 24 h in parallel with apoptosis staining for Annexin V-FITC, where activated caspase 3 was clearly 
visible in the cytoplasm probed with CY3 at 24 h.
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During early apoptosis, the integrity of the cell membrane 
is lost and phosphatidylserine (PS) is exposed for Annexin V 
binding (21). A significant number of SKOV3 cells were stained 
positive for Annexin V, when examined under immunofluores-
cence microscope, suggesting that the cell membrane integrity 
was no longer intact as Annexin V labeled with FITC was able 
to bind to PS, which is usually present on the intracellular leaflet 
of the healthy cells. However, it is translocated to the outer 
leaflet during apoptosis. Hence, it provided the first evidence that 
SKOV3 cells were undergoing apoptosis following the treatment 
with C1q or globular heads for 24  h (Figure  3). Trypan blue 
exclusion (Figure 2A) and MTT assays (Figure 2B), as well as 
FACS analysis (Figure 4) of treated SKOV3 cells, validated C1q-
induced apoptosis of SKOV3 cells. Thus, we investigated if the 
levels of pro-apoptosis factors such as Fas and Bax were altered 
following C1q treatment of SKOV3 cells. This subsequently led 
us to examine the TNF-induced apoptosis pathway.
Tumor necrosis factor-α is a prototypical member of pro-
inflammatory cytokine family that performs various roles in 
inflammation and cell death (22). Members of the TNF family 
are associated with a wide range of immune processes and play 
an important role in cancer immune surveillance For example, 
TNF-α can mediate apoptosis selectively in tumor cells via 
death receptors involving TRAIL/FasL ligands (23). Following 
treatment of SKOV3 cells with C1q or globular head modules, 
the gene expression of TNF-α was upregulated at 6 h (C1q) and 
12  h (C1q, ghA, ghB, and ghC; Figure  5A), which underwent 
apoptosis by 24 h. Interaction of TNF-α with its receptor TNFR1 
can cause upregulation of NF-κB, as was the case in our study 
(Figure  5B). Fas mRNA upregulation is observed, as expected 
(Figure  6A), suggesting that Fas, a receptor for FasL and a 
member of TNF receptor family, mediated apoptosis crosstalk. 
Intriguingly, Bax, a marker of dysfunctional mitochondria, was 
also seen to be transcriptionally upregulated (Figure  6B). Bax 
FigUre 8 | (a) relative quantification comparisons of mammalian target of rapamycin (mTOr) (a), raPTOr (b), and ricTOr (c) mrna expression in 
sKOV3 cells treated with c1q, gha, ghB, and ghc (10 µg/ml) at 6 h. Significance was obtained using the unpaired one-way ANOVA test (*p < 0.05, *p < 0.01, 
and ***p < 0.001) (n = 3). (B) Immunofluorescence microscopy to show the presence of mTOR detected abundantly in the cytoplasm (green) of the untreated cells, 
compared to SKOV3 cells treated with C1q and globular heads at 15 h time point.
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FigUre 9 | illustration of the likely apoptosis pathway in action following c1q binding to sKOV3 cells. Exogenous treatment of SKOV3 cells with C1q and 
individual globular head modules can induce upregulation of TNF-α and Fas. TNF-α stimulation triggers two parallel, but contrasting, pathways: the pro-apoptotic 
caspase (15) and the anti-apoptotic NFκB-IκB inhibitor of apoptosis proteins (IAP) pathway (16). The cell survival or death, however, depends upon interactions 
among the components of these two pathways as well as other factors such as mitochondrial dysfunction (15, 16). TNF-α can bind to TNF type I receptor (TNFR1), 
which is then internalized to first form a complex with TNFR1-associated DEATH domain, receptor-interacting protein 1 (RIP1), TNF receptor-associated factor 2 
(TRAF2), and cellular inhibitor of apoptosis protein-1 (c-IAP1) (complex I), triggering the upregulation of nuclear factor-κB (NF-κB). A second complex (complex II) is 
later formed when complex I bind to Fas-associated protein with death domain (FADD), which is recruited upon activation of Fas (15, 17). Complex II subsequently 
causes downstream activation of apoptosis signal by activating caspase cascade, resulting in the cleavage of initiator caspase 8 and effector caspase 3 leading to 
apoptosis (15, 17–19). However, NF-κB upregulation may intersect apoptotic pathway as it can promote the induction of various cellular apoptosis inhibitors such as 
TRAF1, TRAF2, cIAP-1, c-IAP-2, and X-linked inhibitor of apoptosis protein (XIAP) (15, 20).
acts as a signal for the release of apoptogenic factors such as 
cytochrome c, Smac (second mitochondria-derived activator of 
caspase)/DIABLO (direct inhibitor of apoptosis protein-binding 
protein), apoptosis-inducing factor, Omi/HtrA2, or endonuclease 
G from the mitochondria. Release of Smac/DIABLO and Omi/
HtrA2 into cytosol has been shown to promote caspase activation 
by antagonizing the IAPs, which are formed following the NF-κB 
upregulation (16). This suggests that Bax upregulation in our 
study may have negated the effects of NF-κB signaling pathway 
to cause inhibition of apoptosis. In addition, Bax can also trigger 
caspase activation by forming a cytochrome c/apoptotic protease 
activating factor 1/caspase 9-complex, which can further cause 
cleavage of caspase 3, or by proceeding via caspase-independent 
death effectors (16, 24–26).
SKOV3 cell line has previously been reported to have a dys-
functional apoptosome, which causes the activation of caspase 9, 
to some extent, to further cleave caspase 3 (27). This is supported 
by our results since activation of caspase 9 was observed (data not 
shown), which was unable to activate caspase 3, suggesting that 
cleaved caspase 3 (Figure 7B) could not have arisen exclusively 
due to mitochondrial pathway and validated a crosstalk between 
intrinsic and extrinsic pathways. This observation appears to sug-
gest that C1q-induced apoptosis in SKOV3 cells had taken place, 
primarily via the extrinsic pathway.
Ovarian cancer cells, including SKOV3 cancer cell line, 
exhibit constitutive activation of Akt/mTOR survival pathway, 
thus protecting the cancer cells from apoptosis (28). mTOR, 
a serine–threonine kinase, upon activation by Akt, forms 
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